Ionis Pharmaceuticals, Inc.: 10-Q filed 2012-11-06

Name: Ionis Pharmaceuticals, Inc.: 10-Q filed 2012-11-06
Creator: Ionis Pharmaceuticals, Inc.

What Ionis Pharmaceuticals, Inc. reported in its quarterly report filed 2012-11-06 (fiscal Q3 2012): 29 published measures, 82 facts as tagged in accession 0001104659-12-074712.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-11-06
Fiscal period: fiscal Q3 2012
Accession: 0001104659-12-074712 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ionis Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-09-30	485,681,000	USD
At 2011-12-31	484,894,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2012-09-30	315,404,000	USD
At 2011-12-31	313,460,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-09-30	170,277,000	USD
At 2011-12-31	171,434,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-09-30	84,563,000	USD
At 2011-12-31	65,477,000	USD
At 2011-09-30	55,263,000	USD
At 2010-12-31	70,052,000	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	-34,159,000	USD	274
2011-01-01 to 2011-09-30	-89,188,000	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	1,033,000	USD	274
2011-01-01 to 2011-09-30	8,934,000	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	11,601,000	USD	92
2012-01-01 to 2012-09-30	82,176,000	USD	274
2011-07-01 to 2011-09-30	20,713,000	USD	92
2011-01-01 to 2011-09-30	66,683,000	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	40,281,000	USD	274
2011-01-01 to 2011-09-30	-1,257,000	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	12,964,000	USD	274
2011-01-01 to 2011-09-30	75,656,000	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-09-30	-904,329,000	USD
At 2011-12-31	-841,488,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	100,680,000	shares	92
2012-01-01 to 2012-09-30	100,351,000	shares	274
2011-07-01 to 2011-09-30	99,687,000	shares	92
2011-01-01 to 2011-09-30	99,620,000	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	100,680,000	shares	92
2012-01-01 to 2012-09-30	100,351,000	shares	274
2011-07-01 to 2011-09-30	99,687,000	shares	92
2011-01-01 to 2011-09-30	99,620,000	shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-706,000	USD	92
2012-01-01 to 2012-09-30	-704,000	USD	274
2011-01-01 to 2011-09-30	11,000	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-09-30	92,598,000	USD
At 2011-12-31	96,615,000	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-28,046,000	USD	92
2012-01-01 to 2012-09-30	-42,805,000	USD	274
2011-07-01 to 2011-09-30	-22,316,000	USD	92
2011-01-01 to 2011-09-30	-52,484,000	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-09-30	361,586,000	USD
At 2011-12-31	360,139,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	5,937,000	USD	92
2012-01-01 to 2012-09-30	16,335,000	USD	274
2011-07-01 to 2011-09-30	4,773,000	USD	92
2011-01-01 to 2011-09-30	11,624,000	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-09-30	51,601,000	USD
At 2011-12-31	76,112,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-09-30	5,256,000	USD
At 2011-12-31	8,300,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	39,647,000	USD	92
2012-01-01 to 2012-09-30	124,981,000	USD	274
2011-07-01 to 2011-09-30	43,029,000	USD	92
2011-01-01 to 2011-09-30	119,167,000	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	36,551,000	USD	92
2012-01-01 to 2012-09-30	115,700,000	USD	274
2011-07-01 to 2011-09-30	39,924,000	USD	92
2011-01-01 to 2011-09-30	110,178,000	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-09-30	101,193,132	shares
At 2011-12-31	100,042,976	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2012-09-30	846,000	USD
At 2011-12-31	-770,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2012-09-30	11,900,000	USD
At 2011-12-31	18,655,000	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-38,345,000	USD	92
2012-01-01 to 2012-09-30	-63,545,000	USD	274
2011-07-01 to 2011-09-30	-26,882,000	USD	92
2011-01-01 to 2011-09-30	-64,754,000	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-37,761,000	USD	92
2012-01-01 to 2012-09-30	-61,225,000	USD	274
2011-07-01 to 2011-09-30	-28,434,000	USD	92
2011-01-01 to 2011-09-30	-66,867,000	USD	273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-37,639,000	USD	92
2012-01-01 to 2012-09-30	-62,841,000	USD	274
2011-07-01 to 2011-09-30	-26,882,000	USD	92
2011-01-01 to 2011-09-30	-64,765,000	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	3,096,000	USD	92
2012-01-01 to 2012-09-30	9,281,000	USD	274
2011-07-01 to 2011-09-30	3,105,000	USD	92
2011-01-01 to 2011-09-30	8,989,000	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	2,000	USD	273

Inspect the source

Entity: Ionis Pharmaceuticals, Inc. / CIK 0000874015
Captured: 2026-09-19T11:15:03.040Z
SEC response SHA-256: 1156fe0cb26dcc7b40e41723fe2685b758c89b1d56f81659b360ba07b6e6544c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000874015.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))